Cardioprotective effects of incretin during ischaemia-reperfusion

• Main Authors: Chinda K., Chattipakorn S., Chattipakorn N.
• Format: Review
• Language: English
• Published: 2014
• Online Access: http://www.ncbi.nlm.nih.gov/pubmed/22496404; http://www.scopus.com/inward/record.url?eid=2-s2.0-84864380749&partnerID=40&md5=f6b2a648b1ab5bfe4c12b881b8e13089; http://cmuir.cmu.ac.th/handle/6653943832/3821
• Institution: Chiang Mai University

Incretin is a gut derived peptide hormone secreted in the intestine after food ingestion, and is degraded rapidly after secretion by dipeptidyl peptidase (DPP)-4. Incretin-based therapy, such as glucagon-like peptide (GLP)-1 and the DPP-4 inhibitor, has been proposed as a new therapeutic approach for the treatment of type 2 diabetic patients. In the past few years, growing evidence also demonstrated the cardioprotective effects of incretin-based therapy, especially during ischaemia-reperfusion (I/R) injury in both the animal models and in clinical studies. However, inconsistent reports exist regarding the use of these pharmacological interventions. In this article, a comprehensive review regarding both basic and clinical studies reporting the effects of GLP-1 and DPP-4 inhibitors on I/R hearts is presented and discussed. The consistent findings as well as controversial results are summarised, focusing on the effects of incretin on the infarct size, left ventricular function and haemodynamic improvement during an I/R injury. © The Author(s) 2012.